Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.

Fokas E; Prevo R; Pollard JR; Reaper PM; Charlton PA; Cornelissen B; Vallis KA; Hammond EM; Olcina MM; Gillies McKenna W

doi:10.1038/cddis.2012.181

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.

Identifier:nobleid.org/w1/20260526/2CB29124

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/2CB29124.svg?ark=w1%2F20260526%2F2CB29124)](https://nobleid.org/work/w1/20260526/2CB29124)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.

Identifier:nobleid.org/w1/20260526/2CB29124

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/2CB29124.svg?ark=w1%2F20260526%2F2CB29124)](https://nobleid.org/work/w1/20260526/2CB29124)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work